Description

Zinnat (cefuroxime) Coated Tablets 500 mg. №10

Ingredients

Active ingredient: Cefuroxime 500 mg.
Other ingredients: Microcrystalline cellulose, croscarmellose sodium, magnesium stearate, hypromellose, titanium dioxide, polyethylene glycol.

Dosage

Adults: The usual dose is 250 mg to 500 mg every 12 hours.
Children: The dose is based on body weight and must be determined by your doctor.

Indications

Zinnat tablets are indicated for the treatment of infections caused by susceptible strains of bacteria in the following conditions: respiratory tract infections, urinary tract infections, skin and soft tissue infections, bone and joint infections.

Contraindications

Do not use Zinnat if you are allergic to cefuroxime or any other cephalosporin antibiotic.

Directions

Take Zinnat tablets by mouth with or without food as directed by your doctor. Do not crush or chew the tablets.

Scientific Evidence

Cefuroxime, the active ingredient in Zinnat tablets, has been extensively studied for its efficacy in treating various bacterial infections. Research published in the Journal of Antimicrobial Chemotherapy has shown cefuroxime to be highly effective against a wide range of pathogens, making it a valuable choice for clinicians in the management of infections.

Additional Information

Zinnat tablets should be stored at room temperature away from light and moisture. Keep out of reach of children. It is important to complete the full course of treatment as prescribed by your healthcare provider to ensure the infection is fully treated.

Pharmacological Effects: Cefuroxime works by interfering with the formation of the bacterial cell wall, leading to the death of the bacteria. It exhibits bactericidal activity against a wide range of gram-positive and gram-negative bacteria.

Clinical Trials: Clinical trials have demonstrated the effectiveness of cefuroxime in the treatment of various infections, with favorable outcomes and a good safety profile. A study published in the International Journal of Infectious Diseases highlighted the efficacy of cefuroxime in the management of community-acquired pneumonia.